PMID- 10670651 OWN - NLM STAT- MEDLINE DCOM- 20000316 LR - 20210308 IS - 1079-9907 (Print) IS - 1079-9907 (Linking) VI - 20 IP - 1 DP - 2000 Jan TI - Acute-phase proteins and hematologic values in ovine lentivirus-infected lambs treated with recombinant ovine IFN-tau. PG - 41-53 AB - To evaluate changes in complete blood cell (CBC) counts, haptoglobin and fibrinogen in ovine lentivirus (OvLV)-infected lambs treated with recombinant ovine interferon-tau (rOVIFN-tau), 24 lambs were allocated to one of four groups (n = 6 per group): (1) virus + rOvIFN-tau, VI, (2) virus + placebo, VP, (3) no virus + rOVIFN-tau, NVI, and (4) no virus + placebo, NVP. Three lambs in each group were treated once a day for 12 weeks, and the remaining 3 lambs were treated for 33 weeks. Blood was collected at days 0, 7, and 10 and at weeks 2-10, 12, 32, and 33 to determine CBC counts, as well as haptoglobin and fibrinogen levels. Hematologic values remained within normal limits in all groups. However, hemoglobin (Hb), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), and packed cell volume (PCV) values decreased (p < 0.05) in the two rOvIFN-tau-treated groups (VI and NVI) compared with the placebo-treated (VP and NVP) groups. Both rOvIFN-upsilon and OvLV had a mild negative effect on neutrophil numbers. Although Hb, MCV, MCHC, PCV, and neutrophil values declined in the rOvIFN-tau-treated lambs compared with the placebo-treated lambs, these values remained within the reference range for sheep. Experimental lambs did not show adverse clinical signs associated with OvLV infection or as a result of rOvIFN-tau treatment. The lack of significant side effects of high-dose rOvIFN-tau in sheep and previous reports of broad-spectrum and cross-species antiviral activity suggest that rOvIFN-tau warrants further investigation as an antiviral therapeutic agent. FAU - de la Concha-Bermejillo, A AU - de la Concha-Bermejillo A AD - Department of Veterinary Pathobiology, Texas A&M University Agricultural Experiment Station, San Angelo 76901, USA. adelaconcha@cvm.tamu.edu FAU - Singh, B AU - Singh B FAU - Whitney, M S AU - Whitney MS FAU - Bazer, F W AU - Bazer FW LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - J Interferon Cytokine Res JT - Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research JID - 9507088 RN - 0 (Acute-Phase Proteins) RN - 0 (Antiviral Agents) RN - 0 (Haptoglobins) RN - 0 (Interferon Type I) RN - 0 (Pregnancy Proteins) RN - 0 (Recombinant Proteins) RN - 0 (interferon tau) RN - 9001-32-5 (Fibrinogen) SB - IM MH - Acute-Phase Proteins/*analysis MH - Animals MH - Antiviral Agents/pharmacology/*therapeutic use MH - *Blood Cell Count MH - *Erythrocyte Indices MH - Fibrinogen/analysis MH - Haptoglobins/analysis MH - Interferon Type I/pharmacology/*therapeutic use MH - Lentivirus Infections/*blood/therapy MH - Male MH - Pneumonia, Progressive Interstitial, of Sheep/blood/*therapy MH - Pregnancy Proteins/pharmacology/*therapeutic use MH - Recombinant Proteins/pharmacology/therapeutic use MH - Sheep/*blood/virology MH - Single-Blind Method EDAT- 2000/02/12 09:00 MHDA- 2000/03/18 09:00 CRDT- 2000/02/12 09:00 PHST- 2000/02/12 09:00 [pubmed] PHST- 2000/03/18 09:00 [medline] PHST- 2000/02/12 09:00 [entrez] AID - 10.1089/107999000312720 [doi] PST - ppublish SO - J Interferon Cytokine Res. 2000 Jan;20(1):41-53. doi: 10.1089/107999000312720.